Deutsche Bank: Quantifying the Impact of AI-Enabled Clinical Trial Delivery
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
Deutsche Bank examines the potential of artificial intelligence and machine learning (AI/ML) across pharmaceutical clinical trials, focusing on a quantified view of the technology's impact on cost and timelines. The analysis indicates that AI/ML can materially ease the resource burden of Phase III trials and compress overall study duration. Although the pharmaceutical industry has historically been slow to adopt new technologies, AI-enabled trial delivery shows clear scope for efficiency gains. Based on industry data, the report quantifies the opportunity: deploying AI/ML solutions in clinical trials can reduce resource burden by up to 28% and shorten trial timelines by 18% on average. The logic runs from AI/ML adoption through optimized trial processes, lower resourcing needs and faster cycle times to improved delivery efficiency and potential industry-wide cost savings. No specific time windows, price forecasts or recommended stocks are provided; the report is intended as a reference for investors in life science tools and biopharmaceutical services.